In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nucleome Looks To Decode The ‘Dark Genome’ With New Technology

Insights From CEO Danuta Jeziorska

Executive Summary

Despite accounting for 98% of our DNA, the ‘dark genome’ has yet to be effectively harnessed for drug discovery. Nucleome Therapeutics’ new modeling technology could finally provide the tools that have been missing, says CEO Danuta Jeziorska.

You may also be interested in...



Artios Banks $153m On The Back Of Novartis And Merck KGaA Deals

Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.

Immunomodulating Heat-Killed Bacteria Could Become Staple Of Oncology Treatment

UK-based Immodulon Therapeutics is developing novel immunomodulators in the form of heat-killed bacteria, being trialed in combination with other cancer treatments such as checkpoint inhibitors. The biotech is initially looking at underserved areas, including pancreatic cancer.

Pipeline Watch: Phase III Starts In Hemophilia, Alzheimer's

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

UsernamePublicRestriction

Register

IV124835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel